How This Doctor Built New York's First AI-Integrated Fertility Clinic

Fertility treatment often follows standardized protocols using high-dose stimulation, extensive preliminary testing, and uniform medication dosing. Patients may undergo weeks of intake testing and spend thousands on medications that may go unused. Embryo assessment can rely on technicians visually evaluating cells under a microscope and then returning embryos to an incubator. Outcomes may not reflect the patient’s effort, especially when women with good ovarian reserve and motivation still experience poor results. Hormonal profiles, ovarian reserve, and medication response vary widely, yet many clinics start with the same stimulation dose, adjust using limited blood markers, and select embryos through subjective visual assessment. Financial incentives in the traditional model can favor more medication and longer timelines rather than optimal patient outcomes.

"He was good at it. But he kept running into the same wall. Women would come to him in their early 30s, healthy, motivated, with good ovarian reserve, and the system would swallow them whole. Four to eight weeks of intake testing before their first injection. Thousands of dollars in medication, much of it unused. Embryo assessments done by a technician eyeballing cells under a microscope twice a day, then putting the embryos back in an incubator and hoping for the best. They'd leave exhausted and $20,000 lighter, with outcomes that didn't reflect how hard they had worked."

"Photo Credit: Aurea Fertility treatment, like most of medicine, was designed around averages. Clinical protocols are built from population-level data, then applied uniformly. The result is a system that works reasonably well for a theoretical average patient, but that theoretical patient doesn't actually exist. Every woman's hormonal profile, her ovarian reserve, her response to medication, it's distinct. And yet, most clinics start everyone at the same stimulation dose, adjust based on crude blood test markers, and select embryos using subjective visual assessment."

"The pharmaceutical industry has no incentive to change this. More medication means more revenue. Longer treatment timelines mean more monitoring visits, more ultrasounds, more billable touchpoints. The incentives of the traditional fertility model are not always aligned with the patient's best outcome."

Read at Entrepreneur